Gilead Sciences (NASDAQ:GILD) Price Target Raised to $170.00

Gilead Sciences (NASDAQ:GILD) had its target price raised by JPMorgan Chase & Co. from $160.00 to $170.00 in a research note published on Wednesday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on GILD. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Weiss Ratings raised shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Truist Financial decreased their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Finally, Zacks Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $159.26.

Gilead Sciences Stock Up 2.8%

Gilead Sciences stock opened at $151.17 on Wednesday. Gilead Sciences has a 1-year low of $114.02 and a 1-year high of $157.29. The business has a fifty day moving average price of $145.13 and a 200-day moving average price of $136.72. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The stock has a market capitalization of $187.44 billion, a price-to-earnings ratio of -56.62 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the prior year, the company posted $2.01 EPS. The firm’s quarterly revenue was up 10.6% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is -122.85%.

Insider Activity

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total transaction of $432,660.00. Following the completion of the transaction, the insider directly owned 116,684 shares of the company’s stock, valued at approximately $16,828,166.48. This trade represents a 2.51% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the sale, the director owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 105,000 shares of company stock valued at $14,940,540. 0.30% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tilia Fiduciary Partners Inc. lifted its position in Gilead Sciences by 4.3% during the third quarter. Tilia Fiduciary Partners Inc. now owns 22,203 shares of the biopharmaceutical company’s stock valued at $3,309,000 after purchasing an additional 925 shares during the period. Valley Wealth Managers Inc. boosted its holdings in Gilead Sciences by 1.0% in the third quarter. Valley Wealth Managers Inc. now owns 37,526 shares of the biopharmaceutical company’s stock valued at $5,593,000 after purchasing an additional 375 shares during the last quarter. Castleview Partners LLC grew its position in Gilead Sciences by 13.8% during the 3rd quarter. Castleview Partners LLC now owns 7,155 shares of the biopharmaceutical company’s stock worth $1,067,000 after purchasing an additional 869 shares during the period. Stokes Capital Advisors LLC grew its position in Gilead Sciences by 2.5% during the 3rd quarter. Stokes Capital Advisors LLC now owns 36,264 shares of the biopharmaceutical company’s stock worth $5,405,000 after purchasing an additional 894 shares during the period. Finally, Mirador Capital Partners LP raised its stake in shares of Gilead Sciences by 0.6% during the 3rd quarter. Mirador Capital Partners LP now owns 14,182 shares of the biopharmaceutical company’s stock valued at $2,114,000 after buying an additional 83 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analyst support remains broadly favorable. JPMorgan said Gilead’s stock price is expected to rise, while Truist Financial raised its price target. Morgan Stanley also maintained a buy rating, despite lowering its expectations for the shares. JPMorgan analyst expects Gilead stock to rise Truist raises Gilead price target Morgan Stanley buy rating
• Positive Sentiment: Cantor Fitzgerald reaffirmed its overweight rating and set a $155 price target, implying limited additional upside but reinforcing the view that Gilead remains attractive relative to the broader sector.
• Positive Sentiment: Gilead signed a five-year DevOps agreement with Cognizant to improve technology and operational processes. Separately, its oncology collaboration with Nurix was extended by two years, preserving the potential for milestone payments and royalties tied to future therapies. Gilead Cognizant agreement Gilead Nurix collaboration extension
• Neutral Sentiment: The reported October short-interest figure is zero shares, producing a zero-day short-interest ratio. This unusually low reading may reflect a reporting or data issue rather than a meaningful change in investor positioning.
• Negative Sentiment: RBC raised its target from $123 to $126 but retained a sector-perform rating; the target remains materially below the current share price. Morgan Stanley’s lower expectations and modest after-hours weakness also highlight near-term valuation risk. RBC Gilead price target

About Gilead Sciences

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.